Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov;146(5):1180–1193. doi: 10.1016/j.jaci.2020.03.034

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 3 — Defective in vitro granulocytic differentiation and maturation in patient primary cells. A, May-Grünwald Giemsa (MGG) staining of representative cytospins from the index patient (P) and an unrelated healthy control (HC) monitoring in vitro differentiation of CD34⁺ cells on day 4 (D4) to day 14 (D14) as indicated. Blast-like cells are marked by the symbol ∗, differentiating cells are marked by the symbol #, and terminally differentiated cells are marked by the symbol ∗∗. Magnification, ×100. (B) Graphic representation of the different stages of differentiation quantified by expert cytologic evaluation of cytospins in (A). (C) Mean fluorescence index (MFI) of CXCR2 gated on CD66b⁺CD16⁺ neutrophils isolated from whole blood or bone marrow (BM) from the HC and the patient. Unpaired t test. (D) MFI of CD10 on CD66b⁺CD16⁺ neutrophils isolated from whole blood or BM from the HC and the P. Unpaired t test. (E) Flow cytometry plot showing CD62L and CD16 expression gated on live CD66b⁺CD16^med-high cells. (F) Representative MGG staining of peripheral blood smears from the HC and the patient. Magnification, ×50.